Jiewen Peng
Overview
Explore the profile of Jiewen Peng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
621
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Liu T, Chen X, Xu Y, Wu W, Tang W, Chen Z, et al.
Environ Int
. 2019 Jun;
130:104882.
PMID: 31202028
Background: Experimental studies have indicated that alterations in the gut microbiota might play a role in the pathway of diabetes induction resulting from particulate matter pollution with aerodynamic diameters < ...
12.
Chen K, Liang H, Peng J, Zheng Y
Nan Fang Yi Ke Da Xue Xue Bao
. 2018 Dec;
38(11):1300-1305.
PMID: 30514676
Objective: To investigate the expressions of secreted frizzled-related protein 4 (SFRP4) in stage Ⅱ DNA mismatch repair-deficient (dMMR) and mismatch repair- proficient (pMMR) colorectal cancers and explore their clinical significance....
13.
Li X, Huang H, Xu B, Guo H, Lin Y, Ye S, et al.
Cancer Res Treat
. 2018 Oct;
51(3):919-932.
PMID: 30282447
Purpose: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP...
14.
Chen K, Liang H, Peng J, Zheng Y
Indian J Dermatol Venereol Leprol
. 2018 Mar;
85(1):56-59.
PMID: 29536970
Advanced extramammary Paget's disease does not have a standardized treatment guideline as its incidence is low and has been rarely reported in literature. Here we describe a case of metastatic...
15.
Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, et al.
Lancet
. 2016 Aug;
388(10054):1883-1892.
PMID: 27567279
Background: Outcomes are poor for patients with recurrent or metastatic nasopharyngeal carcinoma and no well established first-line chemotherapy is available for the disease. We compared the efficacy and safety of...
16.
Wu J, Song Y, Su L, Xu L, Chen T, Zhao Z, et al.
BMC Cancer
. 2016 Jul;
16:537.
PMID: 27460571
Background: The efficacy and safety of rituximab-based chemotherapy (R-chemo), the standard regimen for patients with diffuse large B-cell lymphoma (DLBCL), which is more common in Asia than in Western countries,...
17.
Dong W, Gong M, Shi Z, Xiao J, Zhang J, Peng J
PLoS One
. 2016 Apr;
11(3):e0152448.
PMID: 27031235
Programmed cell death-1 (PD-1) plays an important inhibitory role in anti-tumor responses, so it is considered as a powerful candidate gene for individual's genetic susceptibility to cancer. Recently, some epidemiological...
18.
Xue C, Hong S, Li N, Feng W, Jia J, Peng J, et al.
Sci Rep
. 2015 Jul;
5:10648.
PMID: 26216071
There is no consensus on the optimal treatment for patients with advanced non-small-cell lung cancer (NSCLC) and stable disease (SD) after gefitinib therapy. This randomized, open-label, multicenter study aimed to...
19.
Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al.
JAMA
. 2014 Dec;
312(23):2521-30.
PMID: 25514302
Importance: Hepatitis B virus (HBV) reactivation is a serious complication for patients with lymphoma treated with rituximab-containing chemotherapies, despite lamivudine prophylaxis treatment. An optimal prophylactic antiviral protocol has not been...
20.
Hu X, Han B, Gu A, Zhang Y, Jiao S, Wang C, et al.
Lung Cancer
. 2014 Sep;
86(2):207-12.
PMID: 25261231
Background: The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients, and this led to...